Safeguard Scientifics, Inc. (NYSE: SFE) 514% HIGHER; announced that it has sold 16 million shares of its position in portfolio company Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.

Immunomedics (Nasdaq: IMMU) 60.1% HIGHER; UCB and Immunomedics announced top-line results from UCB’s phase IIb clinical study comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, also commonly known as lupus). The data from the 12-week dose and regimen-ranging study demonstrated clinical meaningful treatment effect of epratuzumab over placebo in